Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 3/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080533 | 0.81 | IGFBP3 (0.43) | DHODHGPR35PIK3CAKDM4EALDH1A1 | |
| SCHEMBL6595262 | 0.81 | ALOX15 (0.51) | ALOX15DHODHGPR35PDE10AKDM4E | |
| SCHEMBL6080080 | 0.80 | MCL1 (0.46) | DHODHKDM4EALDH1A1TDP1 | |
| SCHEMBL6079891 | 0.79 | MCL1 (0.53) | GPR35ADORA3KDM4EALDH1A1HPGD | |
| SCHEMBL975858 | 0.78 | ALOX15 (0.56) | ALOX15GPR35PDE10AKDM4EALDH1A1 | |
| SCHEMBL4771510 | 0.77 | ALOX15 (0.51) | ALOX15DHODHGPR35ADORA3ERN1 | |
| SCHEMBL6590567 | 0.75 | ERN1 (0.51) | ALOX15DHODHGPR35ERN1 | |
| SCHEMBL6591608 | 0.74 | MCL1 (0.51) | ALOX15GPR35ERN1PDE10AKDM4E | |
| SCHEMBL6080570 | 0.74 | SCN9A (0.43) | DHODHKDM4EIGFBP3EGLN1 | |
| SCHEMBL6080018 | 0.73 | KMO (0.46) | DHODHGPR35KDM4ETDP1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | ALOX15 2210/4885DHODH 188/4885GPR35 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.